MX345019B - Nuevo anticuerpo ctgf antihumano. - Google Patents
Nuevo anticuerpo ctgf antihumano.Info
- Publication number
- MX345019B MX345019B MX2014007681A MX2014007681A MX345019B MX 345019 B MX345019 B MX 345019B MX 2014007681 A MX2014007681 A MX 2014007681A MX 2014007681 A MX2014007681 A MX 2014007681A MX 345019 B MX345019 B MX 345019B
- Authority
- MX
- Mexico
- Prior art keywords
- human ctgf
- ctgf antibody
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011281811 | 2011-12-22 | ||
| PCT/JP2012/083206 WO2013094723A1 (ja) | 2011-12-22 | 2012-12-21 | 新規抗ヒトｃｔｇｆ抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014007681A MX2014007681A (es) | 2014-11-25 |
| MX345019B true MX345019B (es) | 2017-01-11 |
Family
ID=48668601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014007681A MX345019B (es) | 2011-12-22 | 2012-12-21 | Nuevo anticuerpo ctgf antihumano. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9587015B2 (enExample) |
| EP (1) | EP2796550B1 (enExample) |
| JP (1) | JP6040943B2 (enExample) |
| KR (1) | KR20140107507A (enExample) |
| CN (1) | CN104011206B (enExample) |
| AR (1) | AR089425A1 (enExample) |
| BR (1) | BR112014015405A2 (enExample) |
| CA (1) | CA2859627A1 (enExample) |
| EA (1) | EA029290B1 (enExample) |
| ES (1) | ES2665851T3 (enExample) |
| IN (1) | IN2014CN04615A (enExample) |
| MX (1) | MX345019B (enExample) |
| PL (1) | PL2796550T3 (enExample) |
| PT (1) | PT2796550T (enExample) |
| TW (1) | TW201333034A (enExample) |
| WO (1) | WO2013094723A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824777A (zh) * | 2019-03-15 | 2019-05-31 | 辽宁何氏医学院 | 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| EP3981787A4 (en) * | 2019-06-04 | 2022-09-14 | Jiangsu Hengrui Medicine Co., Ltd. | ANTIBODIES AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND ITS USE |
| CN116391041A (zh) * | 2020-12-03 | 2023-07-04 | 江苏恒瑞医药股份有限公司 | 一种含抗结缔组织生长因子抗体的药物组合物 |
| EP4537841A1 (en) | 2022-06-07 | 2025-04-16 | Astellas Pharma, Inc. | Pharmaceutical composition containing anti-integrin alpha-11 antibody for treatment or prevention of aging-related diseases |
| KR20250097820A (ko) | 2022-10-31 | 2025-06-30 | 아스텔라스세이야쿠 가부시키가이샤 | Toll양 수용체 7/8 듀얼 아고니스트 화합물을 포함하는 항체 약물 복합체 |
| WO2024188179A1 (zh) * | 2023-03-10 | 2024-09-19 | 上海济煜医药科技有限公司 | 一种靶向ctgf的抗体或其抗原结合片段及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8808645U1 (de) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen | Anzeigeeinrichtung für Feuerlöscher |
| US6114143A (en) | 1993-03-11 | 2000-09-05 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Anti-HIV monoclonal antibody |
| JP4537507B2 (ja) | 1997-12-25 | 2010-09-01 | アムジェン インコーポレイテッド | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
| US6562618B1 (en) | 1997-12-25 | 2003-05-13 | Japan Tobacco, Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| CN1660911A (zh) | 1998-12-14 | 2005-08-31 | 迈阿密大学 | 结缔组织生长因子片段及其方法和用途 |
| US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| JP2009067678A (ja) | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
-
2012
- 2012-12-21 PT PT128607421T patent/PT2796550T/pt unknown
- 2012-12-21 BR BR112014015405A patent/BR112014015405A2/pt unknown
- 2012-12-21 CA CA2859627A patent/CA2859627A1/en not_active Abandoned
- 2012-12-21 EP EP12860742.1A patent/EP2796550B1/en active Active
- 2012-12-21 JP JP2013550349A patent/JP6040943B2/ja not_active Expired - Fee Related
- 2012-12-21 ES ES12860742.1T patent/ES2665851T3/es active Active
- 2012-12-21 EA EA201491240A patent/EA029290B1/ru not_active IP Right Cessation
- 2012-12-21 US US14/367,081 patent/US9587015B2/en not_active Expired - Fee Related
- 2012-12-21 AR ARP120104933A patent/AR089425A1/es unknown
- 2012-12-21 IN IN4615CHN2014 patent/IN2014CN04615A/en unknown
- 2012-12-21 WO PCT/JP2012/083206 patent/WO2013094723A1/ja not_active Ceased
- 2012-12-21 KR KR1020147020039A patent/KR20140107507A/ko not_active Abandoned
- 2012-12-21 CN CN201280063995.5A patent/CN104011206B/zh not_active Expired - Fee Related
- 2012-12-21 TW TW101148989A patent/TW201333034A/zh unknown
- 2012-12-21 MX MX2014007681A patent/MX345019B/es active IP Right Grant
- 2012-12-21 PL PL12860742T patent/PL2796550T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR089425A1 (es) | 2014-08-20 |
| PL2796550T3 (pl) | 2018-08-31 |
| PT2796550T (pt) | 2018-04-18 |
| EP2796550B1 (en) | 2018-02-28 |
| EA201491240A1 (ru) | 2014-11-28 |
| EA029290B1 (ru) | 2018-03-30 |
| CA2859627A1 (en) | 2013-06-27 |
| KR20140107507A (ko) | 2014-09-04 |
| BR112014015405A2 (pt) | 2017-06-13 |
| US20140343258A1 (en) | 2014-11-20 |
| US9587015B2 (en) | 2017-03-07 |
| WO2013094723A1 (ja) | 2013-06-27 |
| CN104011206B (zh) | 2017-03-08 |
| MX2014007681A (es) | 2014-11-25 |
| JPWO2013094723A1 (ja) | 2015-04-27 |
| EP2796550A4 (en) | 2015-08-19 |
| CN104011206A (zh) | 2014-08-27 |
| EP2796550A1 (en) | 2014-10-29 |
| ES2665851T3 (es) | 2018-04-27 |
| TW201333034A (zh) | 2013-08-16 |
| JP6040943B2 (ja) | 2016-12-07 |
| IN2014CN04615A (enExample) | 2015-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014001370A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| MX2014001371A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| RU2013140625A (ru) | Антитела против ангиопоэтина-2 человека | |
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| IN2014CN04615A (enExample) | ||
| WO2009048537A3 (en) | Humanized antibody | |
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| MX351273B (es) | Nuevo anticuerpo anti-ngf humano. | |
| NZ706986A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
| MX2010009190A (es) | Anticuerpos anti-c5ar humanizados. | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| JP2014530215A5 (enExample) | ||
| WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| WO2014012007A3 (en) | Rspo3 binding agents and uses thereof | |
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| EA201491235A1 (ru) | Варианты полипептидов fc-pol с улучшенным связыванием неонатального рецептора fc | |
| EP2548574A4 (en) | NEW HUMANIZED MONOCLONAL ANTIBODY AGAINST CD20 | |
| NZ603191A (en) | Methods for the treatment of il-1b related conditions | |
| MX347955B (es) | Novedoso anticuerpo anti-receptor de il-23 humano. | |
| CN104245736A (zh) | 抗人死亡受体5胞外区的人源化单克隆抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |